• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22721 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2008     Committee for New Health Technology Assessment (CNHTA) [ATP7A gene, mutation analysis]
2017     Basque Office for Health Technology Assessment (OSTEBA) [ATOMs – Adjustable Transobturator Male System. Device for urinary incontinence]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atidarsagene autotemcel/OTL-200 (metachromatic leukodystrophy) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Atezolizumab in non-small cell lung cancer]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (small cell lung cancer) - Addendum to Commission A19-86]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC) - Benefit assessment according to § 35a SGB V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC; first line) - Benefit assessment according to §35a Social Code Book V - Addendum]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, combination chemotherapy with paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, combination chemotherapy with nab-paclitaxel) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (NSCLC, adjuvant) - Addendum to Commission A22-67]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (non-small cell lung cancer) - Addendum to A17-50]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (hepatocellular carcinoma) - Addendum to Commission A20-97]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Atezolizumab (breast cancer) - Addendum to Commission A19-81]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Atazanavir/cobicistat (Evotaz®) in HIV infection]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ataluren - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ataluren - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [At a glance: screening and management algorithm management of precancerous lesions - cervical cancer and population-based screening]
2006     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Association between nursing capacity and quality of outcome in inpatient care]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Assistive technology – digital tools that involve social stimulation for mental health in later life. An evidence map]]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Assisted reproduction]
2012     Basque Office for Health Technology Assessment (OSTEBA) [Assistance at normal childbirth. Guide for pregnant women, future parents, as well as their partners and relatives]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Assessments tools for risk prediction of cardiovascular diseases]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Assessment process of the research projects submitted to the 2010 call for topics of la Fundació La Marató de TV3. Acquired spinal cord and brain injuries]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Assessment process of research projects submitted to the 2009 calling of the Fundacio La Marato de TV3. Rare diseases]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Assessment on nucleic acid amplification techniques (NAT) for human immunodeficiency, hepatitis C and hepatitis B virus screening in blood banks]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Assessment of the volume-result relationship in specialized care of pediatric cancer]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the systematic treatment of parodontopathies]
2015     Haute Autorite de sante (HAS) [Assessment of the safety and conditions for conducting autologous fat grafting in reconstructive, restorative and cosmetic breast surgery]
2014     Haute Autorite de sante (HAS) [Assessment of the risks associated with aesthetic mesotherapy practices]
2006     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Assessment of the re-designed diagnosis process for colorectal cancer]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Assessment of the re-designed diagnosis process for colorectal cancer]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of the quality of the registration of administrative variables of the minimum basic data set of short-term hospitals of Osakidetza-Basque Health Service in 2005]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Assessment of the PARLER (Programme d'Accès Rapide Lavallois en Rhumatologie) program]
2023     Center for Drug Evaluation (CDE) [Assessment of the optimal implementation strategy for pneumococcal vaccination policies in groups at high risk of invasive pneumococcal disease]
2015     Haute Autorite de sante (HAS) [Assessment of the measurement of cytomegalovirus viral load by gene amplification in allograft recipients]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the LEADER study on liraglutide - rapid report]
2023     Haute Autorite de sante (HAS) [Assessment of the exhaled nitric oxide measurement for asthma management]
2023     Haute Autorite de sante (HAS) [Assessment of the Endotest® saliva test in complex endometriosis diagnosis situations]
2006     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of the effectiveness of the intraoperative detection of the sentry ganglion in solid tumours]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the application of fluoride varnish on milk teeth to prevent the development and progression of initial caries or new carious lesions - rapid report]
2002     Finnish Office for Health Care Technology Assessment (Finohta) [Assessment of telemedicine in the Northern Ostrobothnia hospital district]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of stereotactic radiosurgery for the treatment of patients with brain metastases]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of stereotactic radiosurgery (SRS) for the treatment of vestibular schwannoma requiring intervention]
2014     Haute Autorite de sante (HAS) [Assessment of spinal cord stimulation]
2014     Haute Autorite de sante (HAS) [Assessment of real-time optical endomicroscopy performed during mapping of Barrett's esophagus (BE) (for diagnosis of BE-associated early neoplasia)]
2019     Haute Autorite de sante (HAS) [Assessment of pulp wound protection by direct pulp capping]
2023     The Danish Health Technology Council (DHTC) [Assessment of pocket-sized handheld ultrasound devices for point-of-care examination of patients in emergency departments]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Assessment of Perinatal Outcome after Sustained Tocolysis for Early Labour (APOSTEL II)]
2024     The Danish Health Technology Council (DHTC) [Assessment of non-surgical treatment of distal radius fractures in patients older than 65 years]
2014     Haute Autorite de sante (HAS) [Assessment of non-invasive methods for measuring liver fibrosis in chronic hepatitis B. Initial assessment and follow-up of non-treated adult patients]
2010     Haute Autorite de sante (HAS) [Assessment of medical devices for home infusion]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of lung cancer screening using low-dose computed tomography]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder]
2011     Haute Autorite de sante (HAS) [Assessment of glomerular filtration rate and serum creatinine levels in the diagnosis of chronic kidney disease in adults]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of factors related to the pharmaceutical expenditure in Primary Care, and prescription quality in chronic diseases]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Assessment of effectiveness and safety of Cyberknife and Gamma knife radiosurgery in intra and extracraneal lesions' treatment (update)]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical cancer]
2009     Haute Autorite de sante (HAS) [Assessment of drug-eluting stents]
2024     The Danish Health Technology Council (DHTC) [Assessment of domiciliary non-invasive ventilation for patients with chronic obstructive pulmonary disease]
2015     Haute Autorite de sante (HAS) [Assessment of diagnostic and therapeutic parotid and submandibular sialendoscopy]
2015     Haute Autorite de sante (HAS) [Assessment of cardiovascular magnetic resonance compared to coronography and computed tomography]
2009     Haute Autorite de sante (HAS) [Assessment of breast implants, tissue expanders and external breast prostheses]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Assessment of bilateral cochlear implants in children. Indication criteria for cochlear implants in children and adults]
2012     Haute Autorite de sante (HAS) [Assessment of an epiretinal prosthesis and its implantation procedure]
1999     Finnish Office for Health Care Technology Assessment (Finohta) [Assessment of an electronic referral and teleconsultation system between secondary and primary health care]
2015     Haute Autorite de sante (HAS) [Assessment of an edge-to-edge mitral valve repair clip and its implantation]
2023     The Danish Health Technology Council (DHTC) [Assessment concerning glucose monitoring for the treatment of adult patients with type 1 diabetes]
2019     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Assessment and interventions in care and services for older adults - an evidence map]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Assessment and clinical management of self-harm in adolescence: evidence-based protocol]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment and analysis of studies on rare diseases - Rapid report]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asfotase alfa: assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asfotase alfa (hypophosphatasia) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asfotase alfa (hypophosphatasia) - Addendum to Commission A19-89]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Canary Health Service [Artificial pancreas with dual release of insulin and pramlintide for treatment of type 1 diabetes mellitus]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Artificial liver support systems]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based screening test for emergent large vessel occlusion using non-contrast brain CT images]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for paroxysmal atrial fibrillation using 12-lead electrocardiogram data]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Artificial intelligence-based diagnostic assistant test for acute myocardial infarction using 12-lead electrocardiogram data]
2024     HTA South [Artificial intelligence in breast cancer screening with mammography]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Artificial intelligence for the detection of colorectal precancerous lesions in colonoscopy]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Artificial disc replacement]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Arthroscopy with joint washout in the treatment of knee arthrosis]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Arthroscopy of the knee joint for gonarthrosis]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Arthroplasty register for Germany]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Arthroplasty register for Germany]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Arterial stiffness measurement for cardiovascular risk classification in high blood pressure patients]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Arrhythmia ablation by EnSite NavX electroanatomical mapping]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aromatase inhibitors in female breast cancer]